Marstacimab Anti-TFPI Hemophilia — PatSnap Eureka
Marstacimab Anti-TFPI: Pfizer's Weekly Subcutaneous Race in Hemophilia A and B
Marstacimab (PF-06741086) restores hemostasis by blocking TFPI's Kunitz domain 2, freeing Factor Xa in both hemophilia A and B patients — with or without inhibitors. Explore Phase III BASIS trial signals, IP landscape, and competitive positioning across the non-factor replacement market.
Why TFPI Is the Right Target for Hemophilia A and B
In individuals with hemophilia A (Factor VIII deficiency) or hemophilia B (Factor IX deficiency), the intrinsic tenase pathway is compromised, making the tissue factor-initiated burst of thrombin generation insufficient to sustain clot formation. NIH-published research confirms that TFPI exacerbates this deficit by further limiting extrinsic pathway flux through its Kunitz-type serine protease inhibitor activity.
TFPI contains three Kunitz domains (K1, K2, K3). The K2 domain inhibits Factor Xa (FXa) and the K1 domain inhibits the tissue factor/Factor VIIa (TF/FVIIa) complex. Anti-TFPI antibodies including marstacimab are designed to bind K2, blocking TFPI's inhibition of FXa and thereby augmenting thrombin generation to compensate for the upstream factor deficiency. This "rebalancing" rationale is applicable regardless of whether patients carry inhibitory antibodies against Factor VIII or IX — a key differentiator relative to factor replacement therapies tracked by PatSnap IP analytics.
Retrieved results also reference the role of protein S as a cofactor that enhances TFPI's anticoagulant activity. Targeting the TFPI–protein S interaction axis represents an additional avenue explored in this mechanistic space, though marstacimab's primary epitope remains the K2 domain. The WHO estimates that hemophilia affects approximately 1 in 10,000 people globally, underscoring the scale of unmet need in prophylaxis management.
Marstacimab vs. Emicizumab, Fitusiran & Concizumab
Retrieved results position four subcutaneous prophylaxis programs as the primary competitive field. Hemophilia type coverage, inhibitor status eligibility, and dosing frequency are the critical differentiators.
| Agent | Assignee | Mechanism / Target | Hemophilia A | Hemophilia B | Inhibitor+ Eligible | Dosing | Development Stage |
|---|---|---|---|---|---|---|---|
| Marstacimab (PF-06741086) | Pfizer | Anti-TFPI K2 mAb (IgG4) | ✓ Yes | ✓ Yes Unique | ✓ Both A & B | Weekly SC | Phase III (BASIS) |
| Emicizumab (Hemlibra) | Roche / Chugai | Bispecific Ab — FIXa × FX bridge | ✓ Yes | ✗ No | A only | Weekly / biweekly / monthly SC | Approved (HAVEN trials) |
| Fitusiran | Alnylam / Sanofi | RNAi — antithrombin (SERPINC1) silencing | ✓ Yes | ✓ Yes | ✓ Both | Monthly SC | Approved / Phase III |
Map the full non-factor replacement IP landscape
Track patent filings from Pfizer, Novo Nordisk, Alnylam, and emerging Asian assignees in real time.
Marstacimab Phase III & Assignee Innovation Signals
Key quantitative signals extracted from patent and literature records in this dataset. All values are derived from retrieved results only.
Anti-TFPI Dataset Activity by Assignee Type
Pfizer dominates patent-driven activity; Novo Nordisk shows balanced patent and literature signals; academic institutions are literature-led.
BASIS Phase III Trial: Key Parameters
The BASIS trial enrolled ~235 patients aged ≥12 years across inhibitor-positive and inhibitor-negative strata in hemophilia A and B.
TFPI Kunitz Domain Epitope Strategy: Marstacimab vs. Concizumab
Marstacimab selectively targets K2; concizumab (Novo Nordisk) targets both K1 and K2 — creating IP overlap that warrants FTO monitoring.
Non-Factor Prophylaxis: Mechanism Distribution in Retrieved Dataset
Anti-TFPI antibodies (marstacimab + concizumab) represent the largest share of retrieved patent and literature records in the non-factor rebalancing space.
Four Mechanistic Approaches in the Non-Factor Replacement Field
Retrieved results characterize marstacimab alongside three other modalities competing in the subcutaneous hemophilia prophylaxis market. Each is mechanistically distinct but targets the same clinical goal.
Anti-TFPI mAb — Marstacimab (PF-06741086)
A fully human IgG4 monoclonal antibody targeting TFPI Kunitz domain 2. Administered subcutaneously with a loading dose followed by weekly maintenance. Evaluated in the life sciences-relevant BASIS Phase III trial (NCT03995875) across ~235 patients with severe hemophilia A or B, with and without inhibitors. Phase I/II PK data support a ~14-day terminal half-life enabling weekly dosing with sustained trough TFPI suppression.
Phase III · BASIS Trial · PfizerFitusiran — RNAi Targeting Antithrombin (SERPINC1)
An RNAi therapeutic developed by Alnylam/Sanofi that silences antithrombin (SERPINC1), reducing antithrombin levels to enhance thrombin generation. Mechanistically distinct from TFPI inhibition but serves the same clinical purpose: prophylaxis independent of factor levels or inhibitor status. Retrieved results position fitusiran as a parallel rebalancing approach in the non-factor subcutaneous prophylaxis category. Monthly subcutaneous dosing differentiates it from marstacimab's weekly schedule.
Approved / Phase III · Alnylam/SanofiEmicizumab (ACE910) — Bispecific FIXa × FX Bridge
A bispecific antibody mimicking Factor VIII cofactor function by bridging FIXa and FX, developed by Roche/Chugai. Established as the benchmark comparator for non-factor ABR reduction in hemophilia A. Retrieved records explicitly note emicizumab's limitation to hemophilia A (not B) and frame marstacimab's pan-hemophilia activity as a strategic differentiation point. Emicizumab data appear as the ABR benchmark across retrieved results for industry validation of non-factor prophylaxis.
Approved · Hemophilia A Only · Roche/ChugaiConcizumab — Anti-TFPI K1/K2 (Novo Nordisk)
Retrieved results include patent filings and publications from Novo Nordisk related to concizumab, an anti-TFPI antibody targeting both K1 and K2 Kunitz domains. Appears in retrieved data as a direct competitive program with overlapping patient eligibility (hemophilia A and B, with and without inhibitors). Novo Nordisk's retrieved records encompass Kunitz domain binding characterization and clinical dose-escalation data from explorer phase programs. IP strategists should assess Pfizer's K2-selective epitope claims versus Novo Nordisk's overlapping filings tracked via PatSnap analytics.
Phase III (Explorer) · Novo Nordisk · K1+K2Key Strategic Implications from Retrieved Data
Retrieved patent and literature records surface five strategic signals for IP teams, clinical strategists, and commercial planners tracking the anti-TFPI hemophilia space.
Pan-Hemophilia Coverage Is the Central Commercial Thesis
Retrieved results consistently frame marstacimab's activity in both hemophilia A and B, with and without inhibitors, as its primary competitive advantage over emicizumab (hemophilia A only). IP and clinical strategy in retrieved data both reinforce this positioning as the lead differentiation argument.
Inhibitor-Positive Hemophilia B: Highest Unmet Need
Retrieved results identify inhibitor-positive hemophilia B patients as a population with no approved non-factor prophylaxis option. Emicizumab is unavailable for hemophilia B; bypass agents provide suboptimal prophylaxis. This creates a near-term regulatory pathway with limited competitive overlap — identified as a high-value niche for initial approval and reimbursement access.
Combination Strategies & Next-Generation Anti-TFPI Approaches
Retrieved literature and conference abstracts suggest that anti-TFPI prophylaxis may serve as a bridging strategy for patients awaiting or transitioning from gene therapy, given its independence from factor levels. Retrieved results do not yet include clinical trial data for this combination but flag it as a mechanistic rationale for continued development in severe hemophilia B, where NIH-tracked gene therapy options are actively advancing.
Retrieved patent filings from third-party assignees explore dual-axis rebalancing by simultaneously modulating TFPI and antithrombin pathways. Retrieved results caution that simultaneously inhibiting two anticoagulant pathways amplifies thrombotic risk — a key safety consideration for any combination strategy. The EPO patent database shows active filing activity in this dual-target space from academic and smaller biotech assignees.
Retrieved patent records from academic and biotech assignees describe the protein S–TFPI interaction as a more selective intervention point that could modulate TFPI activity with potentially greater tissue specificity than pan-TFPI K2 blockade. Retrieved results position this as an emerging direction rather than a current competitive threat to marstacimab. Biosimilar and biobetter competition from Asian assignees (notably Chinese and Korean pharmaceutical companies) is flagged in retrieved filings as a longer-term IP risk, trackable via PatSnap's open API.
Marstacimab Anti-TFPI Hemophilia — Key Questions Answered
Marstacimab (PF-06741086) is a fully human IgG4 monoclonal antibody directed against the K2 domain of tissue factor pathway inhibitor (TFPI). By binding the K2 domain, it sterically blocks TFPI's inhibition of Factor Xa (FXa), freeing FXa to contribute to prothrombinase complex assembly and thrombin burst amplification. This restores hemostasis in patients with hemophilia A or B regardless of whether they carry inhibitory antibodies against Factor VIII or IX.
The BASIS Phase III trial (NCT03995875) is a randomized, open-label, parallel-arm study in patients aged 12 years and older with severe hemophilia A or B, with or without inhibitors. The primary endpoint is annualized bleeding rate (ABR). The trial enrolled approximately 235 patients across inhibitor-positive and inhibitor-negative strata. Retrieved results reference interim and primary analyses indicating statistically significant reductions in ABR versus on-demand factor/bypass agent therapy, with the inhibitor-positive stratum showing particularly notable reductions.
Emicizumab is a bispecific antibody mimicking Factor VIII cofactor function, limited to hemophilia A only. Fitusiran is an RNAi therapeutic targeting antithrombin (SERPINC1), applicable across hemophilia A and B. Marstacimab targets TFPI Kunitz domain 2 and is active in both hemophilia A and B, with and without inhibitors — its pan-hemophilia activity is its primary competitive advantage. All three programs converge on weekly or monthly subcutaneous prophylaxis, making dosing frequency, injection burden, and patient preference data critical differentiators.
Thrombotic events are monitored as a primary safety concern given the mechanism of action — relieving physiological anticoagulation. Retrieved clinical records indicate that at therapeutic doses, the rate of thrombotic adverse events in the BASIS program was consistent with the underlying hemophilia population risk without excessively elevated thrombosis, though retrieved data caution that this safety margin requires continued surveillance. Regulatory agencies have required systematic thrombosis monitoring.
Inhibitor-positive hemophilia B patients represent a population with no approved non-factor prophylaxis option. Emicizumab is available only for hemophilia A inhibitor patients, and bypass agents provide suboptimal prophylaxis for hemophilia B inhibitor patients. Marstacimab's mechanism is independent of factor levels or inhibitor status, creating a near-term regulatory pathway with limited competitive overlap — identified in retrieved data as a high-value niche for initial approval and reimbursement access.
Retrieved patent filings from Novo Nordisk (concizumab, targeting K1 and K2 domains), academic institutions, and emerging Asian assignees (Chinese and Korean pharmaceutical companies) suggest the TFPI antibody space is not exclusively Pfizer-held. Pfizer's core filings include composition of matter, method of treatment, and formulation claims for subcutaneous delivery. IP strategists should assess the independence of Pfizer's K2-selective epitope claims relative to Novo Nordisk's overlapping Kunitz domain filings, particularly in jurisdictions where both companies have active prosecution.
Still have questions about marstacimab or anti-TFPI hemophilia intelligence?
Ask PatSnap Eureka InstantlyMap the Full Marstacimab & Anti-TFPI Patent Landscape
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Track Pfizer, Novo Nordisk, and emerging assignees across the non-factor hemophilia prophylaxis space — in real time.
References
- Tissue Factor Pathway Inhibitor — Molecular Biology and Therapeutic Targeting in Hemophilia — Maroney SA, Mast AE, 2020. PubMed Central.
- Anti-Tissue Factor Pathway Inhibitor (TFPI) Therapy for Hemophilia — Mechanism and Clinical Development of Marstacimab — Pabinger I, Tiede A, 2021. PubMed Central.
- PF-06741086 (Marstacimab), a High-Affinity Anti-TFPI Antibody Restoring Hemostasis in Hemophilia A and B Plasma — Chowdary P et al., 2019. PubMed Central.
- BASIS: A Phase 3 Study Evaluating Marstacimab in Patients with Severe Hemophilia A or B with or without Inhibitors — Young G et al. (Pfizer), ASH 2023.
- Anti-TFPI Antibody Compositions and Methods of Use — Pfizer Inc., US10407510B2, 2019. United States Patent.
- Antibodies to Tissue Factor Pathway Inhibitor and Uses Thereof — Pfizer Inc., WO2016205732A1, 2016. PCT/International Patent.
- Concizumab, an Anti-TFPI Antibody, in Patients with Hemophilia A or B — Explorer Phase 2 Trial — Shapiro AD et al. (Novo Nordisk), 2021. PubMed Central.
- Non-Factor Replacement Therapies for Hemophilia: Mechanisms, Clinical Data and Pipeline Comparison — Lenting PJ et al., 2022. PubMed Central.
- Fitusiran — RNAi Therapy Targeting Antithrombin in Hemophilia A and B with and without Inhibitors — Pasi KJ et al. (Alnylam/Sanofi), 2021. New England Journal of Medicine.
- Methods of Treatment of Hemophilia Using Anti-TFPI Antibodies — Pfizer Inc., US20210054074A1, 2021. United States Patent.
- Emicizumab Prophylaxis in Patients with Hemophilia A without Inhibitors — HAVEN 3 Trial — Mahlangu J et al. (Roche/Chugai), 2018. New England Journal of Medicine.
- TFPI Kunitz Domain 2 Epitope Binding and Functional Blockade by Therapeutic Antibodies — Novo Nordisk A/S, EP3368568A1, 2018. European Patent Office.
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.